Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(3E)-5-fluoro‑1‑\[(6-fluoro‑4H‑1,3-benzodioxin‑8‑yl)methyl]–1H-indole–2,3-dione 3–oxime is a synthetic small molecule belonging to the class of benzo[1,3]dioxanes and indole derivatives. It has a molecular formula of C17H12F2N2O4 and a molecular weight of approximately 346.29 g/mol[1][2][4]. The compound is primarily referenced in chemical databases as an experimental or research molecule with no established clinical use or approved therapeutic indication. Structural studies indicate it can bind to mitogen‐activated protein kinase 10 (JNK‐3), suggesting potential as a kinase inhibitor for research purposes[6]. However, there are no published data on its mechanism of action in humans or animals beyond structural binding information.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (3E)-5-fluoro-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-1H-indole-2,3-dione 3-oxime.